>> we are toying around with ruminating (about dosing frequencies) before we indeed know the scientific proof of Squalamine’s probable efficacy. <<
We are discussing the dosing frequency and possible subcutaneous administration because Dr. Levitt mentioned these matters in his talk. Our job is to figure out why he did, and I don’t think we have a convincing answer yet.
Market Data 
Markets 
AI
